RxDoctor Payments Data

Tuere Coulter, MD

Family Medicine · Pearland, TXNPI 1710142880

Payments from drug & device makers

$2,498in general payments, 2019–2025

Across 100 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$537
  • Merz North America, Inc.$183
  • Pfizer$112
  • AbbVie$48
  • Optinose US, Inc.$31
  • plus $132 from 7 others

What the payments were for

  • Travel & lodging$70%
  • Food & beverage$2,491100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,498 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$23,219
Medicare patients
38
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$42,947
MounjaroTirzepatide19$19,743
RybelsusSemaglutide17$18,228
EliquisApixaban19$16,976
Atorvastatin Calcium141$813
Gabapentin55$746
Pravastatin Sodium45$649
Omeprazole31$563
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide22$449
Fluticasone Propionate42$444
Famotidine17$339
Nifedipine ErNifedipine12$332
Celecoxib12$323
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide17$314
Montelukast Sodium22$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,455$61,17562 claims
Lilly USA, LLCMounjaro$537$19,74319 claims
PfizerEliquis$112$16,97619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →